Bicycle Therapeutics (BCYC) Receivables (2019 - 2025)

Bicycle Therapeutics has reported Receivables for 7 years, with the latest figure at $35.6 million in Q4 2025.

• For the quarter ending Q4 2025, Receivables changed 0.15% year-over-year to $35.6 million; the trailing twelve-month figure through Dec 2025 stood at $35.6 million (changed 0.15% YoY), and the FY2025 full-year result was $35.6 million, changed 0.15% from the prior year.
• Receivables for Q4 2025 stood at $35.6 million, down from $46.3 million in the prior quarter.
• The five-year high for Receivables was $76.5 million in Q1 2023, with the low at $2.3 million in Q1 2022.
• Historically, Receivables has averaged $30.7 million across 5 years, with a median of $24.0 million in 2023.
• Annual changes were most pronounced in 2022 — Receivables slumped 83.0% — and 2023, when it soared 3226.61%.
• Bicycle Therapeutics' Receivables stood at $11.9 million in 2021, then jumped by 78.06% to $21.2 million in 2022, then gained by 13.35% to $24.0 million in 2023, then surged by 48.31% to $35.7 million in 2024, then fell by 0.15% to $35.6 million in 2025.
• The last three Receivables figures came in at $35.6 million (Q4 2025), $46.3 million (Q1 2025), and $35.7 million (Q4 2024), per Business Quant data.